{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:12:11Z","timestamp":1779297131433,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer HealthCare Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116730","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T01:15:45Z","timestamp":1775438145000},"page":"116730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial"],"prefix":"10.1016","volume":"240","author":[{"given":"Bertrand","family":"Tombal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-9474","authenticated-orcid":false,"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evgeny","family":"Kopyltsov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2569-4446","authenticated-orcid":false,"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Mendez-Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Littleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shankar","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Verholen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejca.2026.116730_bib1","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2026.116730_bib2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejca.2026.116730_bib3","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/cancers11091355","article-title":"Current treatment options for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Cattrini","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ejca.2026.116730_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40271-018-0349-x","article-title":"Symptoms and impacts in metastatic castration-resistant prostate cancer: qualitative findings from patient and physician interviews","volume":"12","author":"Holmstrom","year":"2019","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.ejca.2026.116730_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clon.2018.11.001","article-title":"Treatment experiences, information needs, pain and quality of life in men with metastatic castrate-resistant prostate cancer: results from the EXTREQOL study","volume":"31","author":"Jenkins","year":"2019","journal-title":"Clin Oncol (R Coll Radio)"},{"issue":"6","key":"10.1016\/j.ejca.2026.116730_bib6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","article-title":"Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review","volume":"10","author":"Hussain","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116730_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","article-title":"Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: a meta-analysis","volume":"173","author":"Ciccarese","year":"2022","journal-title":"Eur J Cancer"},{"issue":"32","key":"10.1016\/j.ejca.2026.116730_bib8","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116730_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.ejca.2026.116730_bib10","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00d72 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejca.2026.116730_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116730_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"ESMO Guidelines Committee. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2026.116730_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116730_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejca.2026.116730_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2026.116730_bib16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13318-019-00577-5","article-title":"Drug-drug interaction potential of darolutamide: in vitro and clinical studies","volume":"44","author":"Zurth","year":"2019","journal-title":"Eur J Drug Metab Pharm"},{"issue":"20","key":"10.1016\/j.ejca.2026.116730_bib17","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116730_bib18","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/oncolo\/oyad254","article-title":"Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in Black patients from the randomized ARASENS trial","volume":"29","author":"Shore","year":"2024","journal-title":"Oncologist"},{"issue":"21","key":"10.1016\/j.ejca.2026.116730_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70029","article-title":"Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: phase 3 ARASENS subgroup analysis","volume":"13","author":"Uemura","year":"2024","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2026.116730_bib20","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000003257.02","article-title":"MP29-02 Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in the North American population from ARASENS","volume":"209","author":"Shore","year":"2023","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ejca.2026.116730_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41391-023-00775-y","article-title":"Safety profile of darolutamide versus placebo: a systematic review and meta-analysis","volume":"27","author":"Turco","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"13","key":"10.1016\/j.ejca.2026.116730_bib22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.ejca.2026.116730_bib23","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116730_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113258","article-title":"Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial","volume":"192","author":"Fizazi","year":"2023","journal-title":"Eur J Cancer"},{"issue":"Suppl 7","key":"10.1016\/j.ejca.2026.116730_bib25","article-title":"Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study","volume":"33","author":"Fizazi","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116730_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.06.010","article-title":"Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial","volume":"154","author":"Smith","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10323","key":"10.1016\/j.ejca.2026.116730_bib27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ejca.2026.116730_bib28","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116730_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113342","article-title":"Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study","volume":"195","author":"Shore","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116730_bib30","doi-asserted-by":"crossref","unstructured":"Grimm M.-O., Von Amsberg G., Heers H., Degener S., Roghmann F., Casuscelli J., et al. 3-weekly docetaxel 75 mg\/m2 vs 2-weekly docetaxel 50 mg\/m2 in combination with darolutamide + ADT in patients with mHSPC: results from the randomised phase I ARASAFE trial. Presented at ESMO, October 17\u201321, 2025; Berlin, Germany. Abstract LBA92.","DOI":"10.1016\/j.annonc.2025.09.108"},{"issue":"8","key":"10.1016\/j.ejca.2026.116730_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.29783","article-title":"Androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer","volume":"7","author":"George","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:23:06Z","timestamp":1779294186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":31,"alternative-id":["S0959804926005101"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116730","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116730"}}